Jyong Biotech Ltd. (MENS)
Nasdaq: MENS · Pharmaceutical Preparations · New Taipei City, TW · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | May 15, 2026 | · | · |
| Research and development | 813 | 927 | 1,071 |
| Sales and marketing | 45 | 44 | 47 |
| General and administrative | 1,749 | 1,085 | 1,679 |
| Total operating expenses | 2,607 | 2,056 | 2,797 |
| Operating income | -2,607 | -2,056 | -2,797 |
| Interest expense | 2,539 | 1,035 | 757 |
| Interest and investment income | 610 | 7 | 56 |
| Total non-operating income (expense) | -2,064 | -963 | -1,603 |
| Income before income taxes | -4,671 | -3,019 | -4,400 |
| Net income | -4,671 | -3,019 | -4,400 |
| Earnings per share, basic | -0.06 | -0.04 | -0.06 |
| Earnings per share, diluted | -0.06 | -0.04 | -0.06 |
| Weighted average shares, basic | 73,011 | 71,567 | 71,567 |
| Weighted average shares, diluted | 73,011 | 71,567 | 71,567 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding